FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer

A new antibody drug conjugate yielded an overall response rate of 44% among patients with advanced disease who had progressed on chemotherapy and immunotherapy.

Read the full article here

Related Articles